



Commercial/Healthcare Exchange PA Criteria

Effective: June 3, 2020

Prior Authorization: Ubrelvy™

Products Affected: Ubrelvy (ubrogepant) oral tablets

Medication Description: Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is distributed throughout the nervous system, and it is concentrated at anatomical sites, such as the trigeminovascular system, which are involved in migraine pathophysiology. Centrally, CGRP is involved in nociceptive transmission through second and third-order neurons and pain modulation in the brainstem. Peripherally, CGRP mediates vasodilation through smooth muscle receptors. CGRP concentrations are elevated during acute migraine attacks and may be chronically elevated in chronic migraineur.

Covered Uses: Acute treatment of migraines with or without aura

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis of migraine headaches
2. Previous therapies tried/failed

Age Restrictions: 18 years or older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

I. Initial Criteria

1. **Migraine, Acute Treatment.** Approve for 1 year if the patient meets the following criteria (A **and** B):
 - A. The patient has a diagnosis of migraine headaches; **AND**
 - B. The patient meets ONE of the following (i or ii):
 - i. The patient has tried at least one triptan therapy; **OR**
 - ii. The patient has a contraindication to triptan(s) according to the prescriber.

II. Continuation Criteria

2. Patient has experienced a positive clinical response to therapy (e.g., reduction in headache pain severity, relief from other migraine symptoms [photophobia, phonophobia or nausea], sustained headache pain relief, and improved ability to function normally).

Last Rev. December 2021



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

References:

1. Ubrelvy™ tablets [prescribing information]. Madison, NJ: Allergan; December 2019.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 3rd edition (beta version). *Cephalalgia*. 2013;33:629-808.
3. MacGregor EA. In the clinic. Migraine. *Ann Intern Med*. 2017;166(7):ITC49-ITC64.
4. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. *Headache*. 2015;52:103-122.
5. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59:1-18.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	6/3/2020
2	Policy update	Added Continuation criteria: Continuation A. Patient has experienced a positive clinical response to therapy (e.g., reduction in headache pain severity, relief from other migraine symptoms [photophobia, phonophobia or nausea], sustained headache pain relief, and improved ability to function normally).	Other criteria	1/11/2021
3	Policy update	Modified Initial Criteria to remove “patient has tried two triptan therapies,” to “patient has tried at least one triptan therapy”	Other Criteria	12/8/2021